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doi:10.1016/j.jtcvs.2006.03.039andomized clinical trials (RCTs) are a fundamental tool for surgical inves-
tigators to validate new therapies, but they are still used sparingly, and the
results are reported in an inconsistent format. This conclusion is highlighted
y the provocative article by Tiruvoipati and colleagues,1 who report in this issue 
he use of the CONSORT statement, a checklist and flowchart used in reporting
esults of RCTs, in the cardiothoracic surgery literature. This important statement is
ndorsed by many medical journals but not by most surgical journals. I strongly
gree with the authors’ major conclusion that
It is therefore important that RCTs are reported in a high quality manner so the
readers could have a clear view on why the study was conducted, how it was
conducted and how it was analyzed. This would be helpful not only in the
immediate appraisal of trials, but also in the long term, when performing
further analyses such as in systematic reviews and meta-analyses.1
They also make the important point that a uniform reporting format about the
esign and methodology of a trial is vital, so that results of subsequent trials can be
ompared with those of previously published reports or so that trial results can be
ppropriately compared in a meta-analysis. If this is not done, there is a real risk that
rial results would not be compared in a valid manner and, as a consequence, that a
otentially effective therapy in surgical patients might be either discarded (because
f false-negative results) or applied improperly (because of false-positive results).
The issue of randomized clinical trials is a conundrum for surgical investigators
f all specialties. This is especially true in the surgical oncology field, where there
re scores of new agents and new technologies that must be validated on the one
and, while the value to these new advances is beneficial to a smaller and smaller
opulation of patients with cancer on the other hand, as we are able to distinguish
maller and smaller cancer subtypes based on genetic and molecular markers. We
re now in an era of rapid and expensive research advances that will make it difficult
o perform randomized trials requiring hundreds (or even thousands) of patients with
arrow indications or eligibility for treatment. This means that we will need to
xamine alternative means, such as using surrogate or biologic end points other than
ultiyear survival rates. The capacity of completing major clinical trials in a timely
anner within the referral practice of a single institution is diminishing rapidly. This
eans that surgical researchers will increasingly depend on multi-institutional (and
ven multinational) clinical trials to address the added or substitutive value of a new
gent or new technology. In addition, the use of surrogate end points to validate new
herapies and new statistical methodologies will allow for more timely, less expen-
ive, but still accurate ways to assess rapidly advancing scientific and technologic
nowledge as it applies to the surgical patient. Thus as we partition patients with
ancer on the basis of more precise molecular markers and customize our treatment
o the biology of smaller and smaller subpopulations of patients with cancer, will we
till be able to perform randomized trials evaluating new combination treatments for
fficacy and safety in a timely manner? Probably not.
This leads to the issue of the role of the surgeon in the conduct of cancer clinical
rials. Certainly we as a surgical research community have used RCTs increasingly
hrough the years, but this methodology is still underused, and even the results of
uch RCTs are not reported in a consistent enough format. This is especially true if
e compare our use with the use of RCTs by our colleagues in medical oncology.
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TSt present, surgical oncologists do not have the training, the
nfrastructure, and the resources that compare with those of
ur counterparts in medical oncology practice, where RCTs
ave been imbedded into their clinical training and practice
o a significant degree, both in academia and in private
ractice. I believe that a major effort must be made by
urgical leaders to incorporate the capability of conducting
linical trials into our surgical training programs and for
ore surgical mentors to be role models for conducting
linical trials to a far greater extent than exists at present.
therwise, we will not be in a position to test novel or
nnovative therapies and will default this responsibility to
ther specialties. This expanded role of the surgeon as a
linical trialist must span all aspects of the process: in the
esign phase (as a principle investigator or co–principle
nvestigator), in the conduct of clinical trials, in the report-
ng of results, and in the knowledge of how (and when) to
ncorporate the results of clinical trials into new standards of
are. If we continue to move in this direction, then our
atients benefit, and the advances of new therapies will be
ncorporated more quickly and uniformly.
The authors of this article made a sage conclusion that
. . . the results of RCTs will have a significant impact
on clinical decision making at all levels it is important
42 The Journal of Thoracic and Cardiovascular Surgery ● Auguto improve the quality of reporting. This may be
achieved by the endorsement of the CONSORT state-
ment by CT journals as well as increasing the aware-
ness of CONSORT statement among the CT surgical
researchers.1
This is so true, not only for patients undergoing cardio-
ascular surgery but also for those who are treated by all
urgical subspecialties.
As a consequence of discussions with Dr Gene Black-
tone during the review of this manuscript, I recommended
o the Editorial Board of the Annals of Surgical Oncology
hat they adopt the CONSORT statement. They agreed, and
e have added it to our “Instructions to Authors.” Hope-
ully, other surgical journals will also adopt this important
tatement as well. I would also join the authors in encour-
ging surgical investigators of all specialties to use the
ONSORT criteria when reporting their RCT results so that
ur studies will be more reproducible and comparable and
o that our patients will maximally benefit.
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